Education
About Us
Working with TipRanks
Follow Us
RenovoRx (RNXT)
NASDAQ:RNXT
Top Page
RenovoRx
(NASDAQ:RNXT)
Select Model
Select Model
Rating:49Neutral
Price Target:―
RenovoRx's overall stock score reflects significant financial instability with persistent losses and negative cash flows. Despite technical analysis suggesting some short-term upward momentum, the company's valuation is weakened by a negative P/E ratio and lack of profitability. The absence of earnings call data and corporate events limits further insights into potential improvements, maintaining a cautious outlook on its stock performance.
Positive Factors
Innovative Therapy Platform
The proprietary RenovoTAMP platform offers a competitive advantage by enhancing chemotherapy efficacy and reducing side effects, potentially increasing adoption and partnerships in oncology.
Partnership Opportunities
Collaborations can lead to milestone payments and royalties, providing a diversified revenue stream and enhancing the company's financial stability over time.
Equity Improvement
Improved equity indicates better asset management and financial health, potentially increasing investor confidence and reducing reliance on debt.
Negative Factors
Negative Cash Flow
Persistent negative cash flow reflects operational challenges and reliance on external financing, posing risks to long-term sustainability and financial flexibility.
Profitability Challenges
Significant operational losses highlight ongoing profitability issues, limiting the company's ability to reinvest in growth and innovation.
Financial Instability
The company's fragile financial position, marked by persistent losses, undermines its ability to withstand economic fluctuations and invest in future growth initiatives.
RenovoRx (RNXT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$26.85M
Dividend YieldN/A
Average Volume (3M)445.44K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue GrowthN/A
EPS Growth37.89%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding36,649,918
10 Day Avg. Volume485,269
30 Day Avg. Volume445,440
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)6.80
Price to Sales (P/S)708.18
P/FCF Ratio-3.33
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue39.58
Enterprise Value/Gross Profit58.40
Enterprise Value/Ebitda-4.59
Forecast
1Y Price Target
$5.50Price Target Upside653.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RenovoRx Business Overview & Revenue Model
Company DescriptionRenovoRx (RNXT) is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. The company is dedicated to improving patient outcomes by delivering chemotherapy directly to tumors via its proprietary RenovoTAMP (Trans-Arterial Micro-Perfusion) therapy platform. This platform is designed to enhance the efficacy of existing chemotherapeutic agents while minimizing systemic exposure and associated side effects.
How the Company Makes MoneyRenovoRx generates revenue primarily through the development and commercialization of its RenovoTAMP therapy platform. The company aims to monetize its technology through licensing agreements with pharmaceutical companies and healthcare institutions. Additionally, RenovoRx seeks to establish partnerships and collaborations to further develop its therapeutic applications, which can lead to milestone payments and royalties. The company's financial strategy may also include seeking funding through public and private investments to support ongoing research and development efforts.
RenovoRx Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Apr 01, 2026
Earnings Call Sentiment Positive
RenovoRx's earnings call highlights a strong commercial momentum with the expansion of their TAMP therapy and RenovoCath device, coupled with solid financial health and promising clinical trial progress. Despite being in the early stages of commercialization and facing a long sales cycle, the overall sentiment is positive due to the significant advancements and strategic positioning for future growth.Q3-2025 Updates
Positive Updates
Expansion of TAMP Therapy
RenovoRx's TAMP therapy is gaining traction with academic medical centers, NCI-designated cancer centers, and large community hospitals. Early signs of clinical adoption are promising, with repeat use by physicians.
RenovoCath Commercial Momentum
Year-to-date revenue through Q3 was approximately $900,000. The company expanded from 5 to 14 leading cancer centers approved to purchase RenovoCath, with product quotes delivered to 10 additional centers, totaling 24 centers requesting quotes.
Strong Commercial Foundation and Financial Health
RenovoRx reported over $10 million in cash and cash equivalents, sufficient to fund ongoing commercial efforts and clinical trials into 2026. The company maintains fiscal discipline and is exploring multiple financing options to strengthen the balance sheet.
Clinical Trial Progress
The Phase III TIGER PACT trial continues with enrollment expected to complete in early 2026. The Data Monitoring Committee recommended continuing the study after the second interim analysis, indicating potential positive outcomes.
Negative Updates
Relatively New Commercial Launch
RenovoCath's commercialization is still in its early stages with minor sales fluctuations and limited staff handling sales.
Long Sales Cycle
The sales cycle for hospital approvals ranges from several weeks to several months, indicating a slower process for market penetration.
Company Guidance
During RenovoRx's Third Quarter 2025 Conference Call, significant guidance was provided regarding both clinical and commercial advancements. The company reported year-to-date revenue of approximately $900,000 through Q3, with expectations of continued revenue growth into 2026. They have expanded from 5 approved centers at the start of 2025 to 14, with a total of 24 centers requesting quotes for their RenovoCath device. The company is focused on a strategic, data-driven expansion, with plans to add additional sales and marketing personnel to bolster their efforts. Clinically, they are progressing with their Phase III TIGER PACT trial, expecting to complete enrollment in early 2026 and anticipate final data by 2027. With over $10 million in cash and cash equivalents as of September 30, 2025, RenovoRx is well-positioned to fund their ongoing commercial and clinical activities. The company is also exploring various financing options to further strengthen its balance sheet.RenovoRx Financial Statement Overview
Summary
RenovoRx is facing significant financial challenges, with persistent losses and negative cash flows. Despite improvements in revenue and equity, the company's core operations remain unprofitable, and it heavily relies on external financing. The balance sheet shows some asset management improvements, but the overall financial health is fragile, with high operational losses posing a significant risk.Income Statement
RenovoRx shows a slight improvement in revenue with $43,000 reported in the latest year. However, the company faces a challenging profitability situation with a negative net income of $8.8 million and negative EBIT and EBITDA margins, indicating significant operational losses. The gross profit margin is also concerning as it demonstrates no cost of goods sold, which reflects no substantial revenue activities.30
Negative
Balance Sheet
The balance sheet highlights a modest improvement in stockholders' equity, now at $4.48 million, up from a negative position. However, the company maintains a high leverage with a debt-to-equity ratio of 0.05, which could be considered low in relative terms but is risky in the context of negative profitability. The equity ratio is positive, indicating a shift towards better asset management, but overall financial stability remains a concern.40
Negative
Cash Flow
Operating cash flow remains negative at $9.13 million, showing consistent cash outflows from operations. Free cash flow is similarly negative, reflecting the company's reliance on financing activities to sustain operations. This cash flow instability poses a risk to long-term sustainability, despite substantial financing inflows in the past year.35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 928.00K | 43.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 629.00K | 43.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -8.01M | -10.97M | -11.39M | -9.94M | -5.48M | 0.00 |
| Net Income | -11.11M | -8.81M | -10.23M | -9.89M | -6.32M | -3.80M |
Balance Sheet | ||||||
| Total Assets | 11.21M | 8.12M | 1.47M | 7.26M | 16.29M | 1.91M |
| Cash, Cash Equivalents and Short-Term Investments | 10.04M | 7.15M | 1.17M | 6.44M | 15.19M | 1.79M |
| Total Debt | 236.00K | 278.00K | 0.00 | 0.00 | 0.00 | 2.79M |
| Total Liabilities | 3.13M | 3.64M | 4.47M | 1.10M | 938.00K | 16.57M |
| Stockholders Equity | 8.08M | 4.48M | -3.00M | 6.16M | 15.35M | -14.66M |
Cash Flow | ||||||
| Free Cash Flow | -10.40M | -9.14M | -10.26M | -8.81M | -5.93M | -3.53M |
| Operating Cash Flow | -10.38M | -9.13M | -10.26M | -8.81M | -5.92M | -3.53M |
| Investing Cash Flow | -14.00K | -12.00K | 2.03M | -2.03M | -15.00K | 0.00 |
| Financing Cash Flow | 10.88M | 15.12M | 5.01M | 42.00K | 19.33M | 3.20M |
RenovoRx Technical Analysis
Negative
0.73
Price Trends
1.12
Negative
1.15
Negative
1.12
Negative
Market Momentum
-0.10
Positive
35.82
Neutral
16.24
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNXT, the sentiment is Negative. The current price of 0.73 is below the 20-day moving average (MA) of 0.98, below the 50-day MA of 1.12, and below the 200-day MA of 1.12, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 35.82 is Neutral, neither overbought nor oversold. The STOCH value of 16.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNXT.
RenovoRx Risk Analysis
RenovoRx disclosed 67 risk factors in its most recent earnings report. RenovoRx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
RenovoRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $26.85M | ― | -146.61% | ― | ― | 37.89% | |
46 Neutral | $42.73M | -3.75 | -13.15% | ― | ― | 45.97% | |
44 Neutral | $94.58M | -2.47 | -60.06% | ― | 946.61% | -11.30% | |
40 Underperform | $311.38M | -1.53 | -62.25% | ― | ― | 4.71% | |
35 Underperform | $47.01M | ― | -191.12% | ― | ― | -24.38% | |
30 Underperform | $25.59M | -1.78 | ― | ― | ― | 31.09% |
* Healthcare Sector Average
RNXT
RenovoRx
0.78
-0.51
-39.53%
OVID
Ovid Therapeutics
1.22
0.17
16.19%
GRCE
Grace Therapeutics
3.14
-0.14
-4.27%
JSPR
Jasper Therapeutics
1.76
-20.29
-92.02%
NRSN
Neurosense Therapeutics Ltd.
1.07
0.17
18.89%
PEPG
PepGen Inc.
5.09
0.68
15.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.